Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
RESEARCH TOOLSreports
INTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.50 - $5.35
Previous CloseN/A
Volume52.56K
Average Volume (3M)34.54K
Market Cap
N/A
Enterprise Value$50.10M
Total Cash (Recent Filing)$7.46M
Total Debt (Recent Filing)$157.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 08, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding15,180,945
10 Day Avg. Volume59,391
30 Day Avg. Volume34,543
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)95.42
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$6.25Price Target Upside206.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Intensity Therapeutics, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsData from two completed clinical studies evaluating INT230-6 demonstrated favorable patient survival and disease control in patients with advanced soft tissue sarcoma with limited adverse events.
Market PotentialThe combination of improved safety, targeted therapy, and adaptive immune stimulus could enable INT230-6 to capture a significant portion of the solid tumor therapy market.
Bears Say
Financial PerformanceThe company reported no revenues, and a net loss of $0.25 per diluted share, compared to our estimate of no revenues and a net loss of $0.16 per diluted share.
---
Ownership Overview
16.14% Insiders
1.76% Mutual Funds
14.63% Other Institutional Investors
65.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
INTS FAQ
What was Intensity Therapeutics, Inc.’s price range in the past 12 months?
Intensity Therapeutics, Inc. lowest stock price was $1.50 and its highest was $5.35 in the past 12 months.
What is Intensity Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Intensity Therapeutics, Inc.’s upcoming earnings report date?
Intensity Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Intensity Therapeutics, Inc.’s earnings last quarter?
Intensity Therapeutics, Inc. released its earnings results on Mar 13, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.004.
Is Intensity Therapeutics, Inc. overvalued?
According to Wall Street analysts Intensity Therapeutics, Inc.’s price is currently Undervalued.
Does Intensity Therapeutics, Inc. pay dividends?
Intensity Therapeutics, Inc. does not currently pay dividends.
What is Intensity Therapeutics, Inc.’s EPS estimate?
Intensity Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Intensity Therapeutics, Inc. have?
Intensity Therapeutics, Inc. has 15,180,945 shares outstanding.
What happened to Intensity Therapeutics, Inc.’s price movement after its last earnings report?
Intensity Therapeutics, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Intensity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INTS
---
Company Description
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
---
INTS Stock 12 Month Forecast
Average Price Target
$6.25
▲(206.37% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering INTS
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-15.13%
reiterated a buy rating 10 days ago
Copying Robert Wasserman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -15.13% per trade.
---